Lacutamab

First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with mycosis fungoides that express KIR3DL2 New pre...

First data set from TELLOMAK establishes safety, clinical responses and skin improvement in patients with mycosis fungoides that express KIR3DL2 Data support continued development of lacutamab for...

Company to highlight lacutamab data in mycosis fungoides and share data on its next-generation NK cell engager platform, ANKET™ Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA...

First clinical data of mycosis fungoides presented from the TELLOMAK trial Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that...

• Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphoma • Company’s...

TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoides patients advances to Stage 2 earlier than anticipated Company to initiate two new clinical trials to investigate lacutamab...

Virtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today...

Priority Medicines (PRIME) designation supports the potential for lacutamab to benefit Sézary Syndrome patients in need of new treatment options Innate Pharma SA (Euronext Paris: IPH – ISIN...

Innate resumed enrollment of lacutamab TELLOMAK Phase 2 clinical trial for patients with Sézary syndrome and mycosis fungoides Monalizumab Phase 3 study expected to initiate in the second half of 2020...

Innate Pharma to re-activate TELLOMAK trial in the US New GMP-certified batch has been successfully manufactured Conference call to be held today on the lacutamab clinical trial program Innate Pharma...